Celularity CELU Stock
Celularity Price Chart
Celularity CELU Financial and Trading Overview
| Celularity stock price | 1.02 USD |
| Previous Close | 1.01 USD |
| Open | 1.01 USD |
| Bid | 1.02 USD x 500 |
| Ask | 0.84 USD x 100 |
| Day's Range | 0.97 - 1.07 USD |
| 52 Week Range | 0.71 - 4.35 USD |
| Volume | 109.33K USD |
| Avg. Volume | 216.57K USD |
| Market Cap | 30.97M USD |
| Beta (5Y Monthly) | 0.445 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.59 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
CELU Valuation Measures
| Enterprise Value | 99.81M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.8771931 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.1665604 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 3.759 |
| Enterprise Value/EBITDA | -1.848 |
Trading Information
Celularity Stock Price History
| Beta (5Y Monthly) | 0.445 |
| 52-Week Change | -53.87% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 4.35 USD |
| 52 Week Low | 0.71 USD |
| 50-Day Moving Average | 1.08 USD |
| 200-Day Moving Average | 1.64 USD |
CELU Share Statistics
| Avg. Volume (3 month) | 216.57K USD |
| Avg. Daily Volume (10-Days) | 155.43K USD |
| Shares Outstanding | 28.95M |
| Float | 18.87M |
| Short Ratio | 2.36 |
| % Held by Insiders | 36.40% |
| % Held by Institutions | 12.77% |
| Shares Short | 373.2K |
| Short % of Float | 5.59% |
| Short % of Shares Outstanding | 1.28% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -492.15% |
| Gross Margin | 24.39% |
| EBITDA Margin | -203.43% |
Management Effectiveness
| Return on Assets (ttm) | -30.93% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 26.55M USD |
| Revenue Per Share (ttm) | 1.04 USD |
| Quarterly Revenue Growth (yoy) | -77.40% |
| Gross Profit (ttm) | 6.48M USD |
| EBITDA | -54013000 USD |
| Net Income Avi to Common (ttm) | -91800000 USD |
| Diluted EPS (ttm) | -3.59 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 6.18M USD |
| Total Cash Per Share (mrq) | 0.21 USD |
| Total Debt (mrq) | 74.71M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.153 |
| Book Value Per Share (mrq) | -1.32 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -13254000 USD |
| Levered Free Cash Flow (ttm) | 5.38M USD |
Profile of Celularity
| Country | United States |
| State | NJ |
| City | Florham Park |
| Address | 170 Park Avenue |
| ZIP | 07932 |
| Phone | 908 768 2170 |
| Website | https://www.celularity.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 115 |
Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
Q&A For Celularity Stock
What is a current CELU stock price?
Celularity CELU stock price today per share is 1.02 USD.
How to purchase Celularity stock?
You can buy CELU shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Celularity?
The stock symbol or ticker of Celularity is CELU.
Which industry does the Celularity company belong to?
The Celularity industry is Biotechnology.
How many shares does Celularity have in circulation?
The max supply of Celularity shares is 28.95M.
What is Celularity Price to Earnings Ratio (PE Ratio)?
Celularity PE Ratio is now.
What was Celularity earnings per share over the trailing 12 months (TTM)?
Celularity EPS is -3.59 USD over the trailing 12 months.
Which sector does the Celularity company belong to?
The Celularity sector is Healthcare.
Celularity CELU included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}